Safety and Tolerability of CP101, a Full-Spectrum, Oral Microbiome Therapeutic for the Prevention of Recurrent Clostridioides difficile Infection: A Phase 2 Randomized Controlled Trial

Jessica R. Allegretti, Colleen Kelly, Thomas Louie, Monika Fischer, Susy Hota, Bharat Misra, Nick W Van Hise, Eugene F. Yen, Jeffrey Bullock, Michael Silverman, Ian Davis, Sarah McGill, Darrell S. Pardi, Robert Orenstein, Ari Grinspan, Najwa El‐Nachef, Paul Feuerstadt, Thomas J. Borody, Sahil Khanna, Shrish Budree, Zain Kassam